Rebopag 25mg (Eltrombopag)

Introduction

Rebopag 25mg contains Eltrombopag as its active ingredient. It is an oral medication primarily used to treat conditions associated with low platelet counts (thrombocytopenia). Platelets are blood cells that help stop bleeding by forming clots. Low platelet levels can increase the risk of bruising and excessive bleeding.

Eltrombopag belongs to a class of medicines called thrombopoietin receptor agonists (TPO-R agonists). It works by stimulating the bone marrow to produce more platelets, helping reduce bleeding risks in patients with platelet disorders.

Pharmacology and Mechanism of Action

Eltrombopag is a small-molecule thrombopoietin receptor agonist that works by targeting the thrombopoietin receptor (c-Mpl) found on bone marrow stem cells and megakaryocytes (platelet-producing cells).

By binding to the transmembrane region of the receptor, Eltrombopag activates intracellular signaling pathways that:

• Stimulate megakaryocyte growth and differentiation
• Increase platelet production in the bone marrow
• Help maintain safer platelet levels to reduce bleeding risks

Unlike natural thrombopoietin (TPO), which binds to the external receptor site, Eltrombopag binds to a different receptor region, allowing it to work effectively even when natural TPO levels are high.

Clinical Uses

1. Chronic Immune Thrombocytopenic Purpura (ITP)

ITP is an autoimmune disorder where the immune system destroys platelets, leading to low platelet counts and increased bleeding risk.

Rebopag 25mg is prescribed for adults and children who do not respond adequately to treatments such as:

• Corticosteroids
• Immunoglobulins
• Splenectomy (surgical removal of the spleen)

It helps raise platelet counts and may reduce the need for platelet transfusions.

2. Thrombocytopenia Associated with Chronic Hepatitis C Virus (HCV) Infection

Some patients with hepatitis C develop low platelet levels, which can interfere with antiviral treatment.

Eltrombopag helps increase platelet counts, making antiviral treatment safer and more manageable.

3. Severe Aplastic Anemia (SAA)

Rebopag is also used in patients with severe aplastic anemia who do not respond well to immunosuppressive therapy.

In addition to increasing platelets, it may also improve:

• Red blood cell counts
• White blood cell counts

This supports overall bone marrow recovery.

4. Other Off-Label Uses

In some cases, specialists may use Eltrombopag for:

• Chemotherapy-related thrombocytopenia
• Bone marrow failure syndromes
• Certain blood disorders requiring platelet support

Dosage and Administration

The dosage of Rebopag 25mg depends on the condition being treated, liver function, and platelet response.

For Immune Thrombocytopenia (ITP)

• Typical starting dose: 25 mg once daily
• Dose adjustments may be made every 2 weeks based on platelet count
• Maximum dose usually does not exceed 75 mg daily

For Hepatitis C-Related Thrombocytopenia

• Usually starts at 25 mg once daily
• Dosage may be adjusted depending on platelet response

For Severe Aplastic Anemia

• Starting dose may be 50 mg daily
• Gradually increased depending on treatment response
• Maximum dose may reach 150 mg daily under medical supervision

Administration Tips

• Take on an empty stomach, at least 1 hour before or 2 hours after meals.
• Avoid taking it with milk, dairy products, calcium supplements, iron, magnesium, aluminum, or antacids, as these may reduce absorption.
• Take the medicine at the same time each day for best results.

Pharmacokinetics

Absorption

Eltrombopag is absorbed orally, but absorption can be reduced by calcium-rich foods.

Distribution

It binds strongly to plasma proteins and distributes widely in the body.

Metabolism

Primarily metabolized in the liver through enzymes such as CYP1A2 and CYP2C8.

Elimination

The drug is eliminated through urine and feces, with a half-life of approximately 21–32 hours.

Side Effects

Like all medicines, Rebopag (Eltrombopag) may cause side effects.

Common Side Effects

• Headache
• Nausea
• Diarrhea
• Fatigue
• Muscle or joint pain
• Upper respiratory tract infections

Serious Side Effects

1. Liver Toxicity

Eltrombopag may increase liver enzymes, requiring regular liver monitoring.

2. Blood Clots (Thromboembolic Events)

Excessively high platelet levels can increase clotting risks.

3. Bone Marrow Changes

Long-term treatment may rarely lead to bone marrow fibrosis.

4. Cataracts

Some studies suggest a possible increased risk of cataracts during prolonged treatment.

5. Allergic Reactions

Rarely, rash, swelling, itching, or severe allergic reactions may occur.

Seek immediate medical attention if severe symptoms develop.

Precautions and Contraindications

Contraindications

Avoid Rebopag if:

• You are allergic to Eltrombopag or any ingredient in the formulation.

Precautions

• Regular liver function tests are important.
• Platelet counts should be monitored to avoid excessively high levels.
• Patients with a history of blood clots require extra caution.
• Use carefully in patients with kidney or liver disease.
• Avoid combining with other platelet-stimulating medicines unless supervised by a doctor.

Pregnancy and Breastfeeding

The safety of Eltrombopag during pregnancy and breastfeeding has not been fully established. It should only be used when clearly recommended by a healthcare professional.

Drug Interactions

Eltrombopag may interact with several medications.

Calcium-Containing Products

Products containing:

• Calcium
• Iron
• Magnesium
• Aluminum
• Zinc

may reduce drug absorption. Keep at least a 4-hour gap before or after taking Rebopag.

CYP450 Interactions

Medicines affecting CYP1A2 or CYP2C8 enzymes may change Eltrombopag levels in the body.

Antacids

Antacids containing minerals may reduce absorption and should be spaced apart.

Other Platelet-Stimulating Medicines

Combination use requires close monitoring to prevent excessive platelet production.

Monitoring

Patients taking Rebopag 25mg require regular monitoring, including:

• Platelet counts to guide dose adjustments
• Liver function tests (ALT, AST, bilirubin)
• Complete blood count (CBC)
• Eye examinations during long-term use
• Monitoring for signs of bleeding or blood clots

Patient Counseling

Patients using Rebopag should:

• Take the medicine exactly as prescribed.
• Avoid dairy products and mineral supplements close to dose timing.
• Attend regular blood tests and medical appointments.
• Report symptoms like unusual bruising, bleeding, swelling, chest pain, or shortness of breath immediately.
• Avoid stopping the medicine without consulting a doctor.

Conclusion

Rebopag 25mg (Eltrombopag) is an important medication for treating immune thrombocytopenia (ITP), hepatitis C-associated thrombocytopenia, and severe aplastic anemia. By stimulating platelet production in the bone marrow, it helps reduce bleeding risks and supports safer disease management.

However, careful monitoring is essential due to possible risks such as liver toxicity, blood clots, and bone marrow changes. When used under proper medical supervision, Rebopag 25mg can significantly improve platelet counts and quality of life for patients with thrombocytopenia.